Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis

Melanoma Clinical Trial

Official title:

A Phase II Study of Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis (CASTLE-05)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05406466
• Other study ID #: CASTLE-05
• Status: Recruiting
• Phase: Phase 2
• Start date: July 15, 2022
• Est. completion date: August 16, 2024

Study information

• Verified date: November 2022
• Source: Fudan University
• Contact: Peng Wang, MD
• Phone: 86-21-64175590
• Email: wangp413[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus lenvatinib in patients with melanoma liver metastasis.

Description:

Recent studies have suggested that local destruction of tumor tissue by cryoablation induced activation and maturation of dendritic cells and tumor-specific T cells by cross-presentation of tumor antigens. While pd-1 blocking antibody interferes with PD-1 mediated T-cell regulatory signaling. And combination of pd-1 blocking antibody plus lenvatinib showed increased ORR in many type of human cancers. Therefore, the objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus lenvatinib in patients with melanoma liver metastasis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: August 16, 2024
• Est. primary completion date: July 10, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent obtained.

2. Age = 18 years at time of study entry.

3. Participants must have melanoma liver metastasis.

4. Participants must have failed 1 line of systemic regimens due to disease progression or toxicity.

5. Participants who had received previous antiangiogenic therapy were eligible.

6. At least one measurable site of disease as defined by RECIST criteria with spiral CT scan or MRI.

7. Performance status (PS) = 2 (ECOG scale).

8. Life expectancy of at least 12 weeks.

9. Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count = 1,500/L, platelets =75 x103/L; Total bilirubin = 3x upper normal limit; Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) = 5 x upper normal limit (ULN); International normalized ratio (INR) =1.25; Albumin = 31 g/dL; Serum Creatinine = 1.5 x institutional ULN or creatinine clearance (CrCl) = 30 mL/min (if using the Cockcroft-Gault formula )

10. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.

11. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment, adherence to contraceptive measures, scheduled visits and examinations including follow up.

Exclusion Criteria:

1. History of cardiac disease, including clinically significant gastrointestinal bleeding within 4 weeks prior to start of study treatment

2. Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months Prior to the first dose of study drug with the exception of thrombosis of a segmental portal vein.

3. Prior treatment with cryoablation.

4. RFA and resection administered less then 4 weeks prior to study treatment start.

5. Radiotherapy administered less then 4 weeks prior to study treatment start.

6. Major surgery within 4 weeks of starting the study treatment OR subjects who have not recovered from effects of major surgery.

7. Patients with second primary cancer, except adequately treated basal skin cancer or carcinoma in-situ of the cervix.

8. Immunocompromised patients, e.g. patients who are known to be serologically positive for human immunodeficiency virus (HIV).

9. Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is longer.

10. Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to:

1. history of interstitial lung disease

2. Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) coinfection (i.e double infection)

3. known acute or chronic pancreatitis

4. active tuberculosis

5. any other active infection (viral, fungal or bacterial) requiring systemic therapy

6. history of allogeneic tissue/solid organ transplant

7. diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of anti-PD1-monotherapy treatment.

8. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Exceptions: Subjects with vitiligo, hypothyroidism, diabetes mellitus type I or resolved childhood asthma/atopy are an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with Hashimoto thyroiditis, hypothyroidism stable on hormone replacement or psoriasis not requiring treatment are not excluded from the study.

9. Live vaccine within 30 days prior to the first dose of anti-PD1 monotherapy treatment or during study treatment.

10. History or clinical evidence of Central Nervous System (CNS) metastases Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria: I. are asymptomatic and II. have no requirement for steroids 6 weeks prior to start of anti-PD1-monotherapy treatment. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS

11. Medication that is known to interfere with any of the agents applied in the trial.

12. Any other efficacious cancer treatment except protocol specified treatment at study start.

13. Patient has received any other investigational product within 28 days of study entry.

14. Prior therapy with an anti-Programmed cell death protein 1 (anti-PD-1), anti-PD-L1, anti-Programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor (TNFR) family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

15. Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum ß-HCG) at screening.

Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• Tislelizumab
a PD-1 immune check inhibitor
• Lenvatinib
multitargeted receptor tyrosine kinase inhibitor
• Cryoablation
Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	Objective Response Rate according to RECIST 1.1	max 24 months
Secondary	DCR	Disease control rate	max 24 months
Secondary	DoR	Duration of response	max 24 months
Secondary	TTR	Time to response	max 24 months
Secondary	PFS	Progression Free Survival	max 24 months
Secondary	OS	Overall survival	max 24 months
Secondary	Adverse Events	Adverse event (AE)?Treatment emergent adverse event(TEAE)?Serious adverse event (SAE)	max 24 months